Sanofi Consumer 'Very Complementary' To Pharma, Fits In Firm's 'Right Structure'
Executive Summary
Sanofi wants to keep all its current businesses under the same roof, including consumer health, says CEO Olivier Brandicourt. "We think we have now the right structure," Brandicourt responds to question on whether Sanofi would follow other large pharmas in positioning consumer health or other divisions for separation.
You may also be interested in...
Sanofi Offloads Two German OTC Brands, New CEO Prepares To Make Mark
Sanofi's push to concentrate its Consumer Healthcare portfolio on priority categories sees it offload two OTC brands in Germany and Austria. Meanwhile, new Sanofi CEO Paul Hudson has spoken about his intention to review the firm's plans in the OTC market.
GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals
Big pharmas' agreement could put consumer health where Pfizer wants, entirely in its rear-view mirror, and points GSK toward what it wants, more research and development funding freed up for the pharmaceutical ingredient operations that are its chief revenue drivers. All-equity deal, giving GSK 68% control and expected to close in 2019 second half, also likely will boost investors' confidence in the firms as both have been dogged by pressure to sell, spin-off or otherwise divest their consumer businesses.
Schiff Supplements, MJN Formulas, Other Reckitt Benckiser Consumer Brands Get Their Own Home
UK manufacturer in January begins operating with a separate health care division, representing 60% of sales with products including Schiff supplements and Mead Johnson infant and adult formulas, and a home care/hygiene division led by Lysol disinfectants. The plan piques analysts' expectations that operating the divisions separately will lead to divesting one.